ly 353381 has been researched along with eflornithine in 1 studies
Studies (ly 353381) | Trials (ly 353381) | Recent Studies (post-2010) (ly 353381) | Studies (eflornithine) | Trials (eflornithine) | Recent Studies (post-2010) (eflornithine) |
---|---|---|---|---|---|
70 | 12 | 15 | 2,377 | 93 | 268 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fabian, CJ; Kimler, BF | 1 |
1 review(s) available for ly 353381 and eflornithine
Article | Year |
---|---|
Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
Topics: Aneuploidy; Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Clinical Trials, Phase II as Topic; Cyclooxygenase Inhibitors; Disease Progression; Eflornithine; Endpoint Determination; Enzyme Inhibitors; Estrogens; Female; Fenretinide; Gonadotropin-Releasing Hormone; Humans; Hyperplasia; Isoflavones; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Polyamines; Precancerous Conditions; Protein-Tyrosine Kinases; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Uterine Neoplasms | 2001 |